These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 355012)

  • 41. Humoral immunity conferred by the HDCS rabies vaccine Mérieux administered after exposure: 151 cases with and without specific immune globulin of human origin. Preliminary communication.
    Méan F; Steck F; Tanner F
    Dev Biol Stand; 1978; 40():159-61. PubMed ID: 680389
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Comparison of PVRV and HDCV rabies vaccines as to immunity, reliability and protective value].
    Hacibektaşoğlu A; Inal A; Eyigün C; Barut A; Türkay FA
    Mikrobiyol Bul; 1992 Jan; 26(1):26-36. PubMed ID: 1574019
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Post-exposure use of human diploid cell culture rabies vaccine.
    Kuwert EK; Marcus I; Werner J; Scheiermann N; Höher PG; Thraenhart O; Hierholzer E; Wiktor TJ; Koprowski H
    Dev Biol Stand; 1976 Dec 13-15; 37():273-86. PubMed ID: 1031689
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evaluation of cytokines concentration and percentage of survival of rabies virus-infected mice submitted to anti-rabies Vero-cell propagated vaccine and P. acnes.
    Megid J; Appolinario CM; Mazzini AM; Almeida MF
    Vet Immunol Immunopathol; 2006 Nov; 114(1-2):192-6. PubMed ID: 16930720
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Suckling mouse brain rabies vaccine supplemented with an adjuvant. Its use in cattle].
    Fuenzalida E; Díaz AM; Rivenson S
    Rev Asoc Argent Microbiol; 1978; 10(2):47-53. PubMed ID: 756571
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Rabies post-exposure prophylaxis vaccination with purified chick embryo cell vaccine (PCECV) and purified Vero cell rabies vaccine (PVRV) in a four-site intradermal schedule (4-0-2-0-1-1): an immunogenic, cost-effective and practical regimen.
    Ambrozaitis A; Laiskonis A; Balciuniene L; Banzhoff A; Malerczyk C
    Vaccine; 2006 May; 24(19):4116-21. PubMed ID: 16545510
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A semi-quantitative serological method to assess the potency of inactivated rabies vaccine for veterinary use.
    Liu Y; Zhang S; Zhang F; Hu R
    Virol Sin; 2012 Aug; 27(4):259-64. PubMed ID: 22899435
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [NIH potency tests with inactivated rabies vaccines (author's transl)].
    Barth R; Jaeger O
    Zentralbl Bakteriol B; 1979; 169(5-6):488-94. PubMed ID: 545949
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Production of an inactivated rabies vaccine in primary dog kidney cells.
    van Wezel AL; van Steenis G
    Dev Biol Stand; 1978; 40():69-75. PubMed ID: 98375
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Collaborative study for validation of a serological potency assay for rabies vaccine (inactivated) for veterinary use.
    Krämer B; Bruckner L; Daas A; Milne C
    Pharmeur Bio Sci Notes; 2010 Oct; 2010(2):37-55. PubMed ID: 21144488
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Potency testing of veterinary rabies vaccines: replacement of challenge by in vitro testing: considerations for development of alternative assays.
    Lewis CE; Fry AM; Hermann JR; Siev D; Dusek DM; Gatewood DM
    Dev Biol (Basel); 2012; 134():29-33. PubMed ID: 22888592
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of homologous or heterologous antiserum on neutralizing-antibody response to rabies vaccine.
    Archer BG; Dierks RE
    Bull World Health Organ; 1968; 39(3):407-17. PubMed ID: 5303907
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A relevant in vitro ELISA test in alternative to the in vivo NIH test for human rabies vaccine batch release.
    Gibert R; Alberti M; Poirier B; Jallet C; Tordo N; Morgeaux S
    Vaccine; 2013 Dec; 31(50):6022-9. PubMed ID: 24161572
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Clinical endpoints during rabies vaccine control tests].
    Hartinger J; Folz T; Cussler K
    ALTEX; 2001; 18(1):37-40. PubMed ID: 11248849
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Potency testing of veterinary vaccines, rabies vaccines as an example.
    Bruckner L; Palatini M; Ackermann M; Müller HK; McCullough K; Kihm U
    ALTEX; 1989; 6(2):46-58. PubMed ID: 11208274
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Titration of serum and antirabies immunoglobulins by the radial immunodiffusion method].
    Mouillot L; Chaniot S; Piat A; Netter R
    Dev Biol Stand; 1978; 40():243-6. PubMed ID: 98374
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Potency testing of inactivated rabies vaccines. Problems posed by the use of the Habel test].
    Aubert MF; Andral L
    Comp Immunol Microbiol Infect Dis; 1979; 1(4):341-9. PubMed ID: 318239
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Rabies vaccine standards: comparison of the 5th and 6th WHO international reference standards to the USDA veterinary reference standard.
    Hermann J; Fry A; Reising M; Patterson P; Siev D; Gatewood D
    Vaccine; 2012 Nov; 30(48):6892-6. PubMed ID: 22981761
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A study of candidate rabies vaccines for a national reference preparation for the evaluation of antigenic potency.
    Ralph NM; Romanova LN; Grachev VP; Dzagurov SG; Klyueva EV; Elbert LB; Gribencha LF; Shamshuvalieva AE; Finogenova EV; Kodkind GH
    J Biol Stand; 1983 Oct; 11(4):279-88. PubMed ID: 6643509
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect on immunity to challenge and antibody response of variation in dosage schedule of rabies vaccine in mice.
    HABEL K
    Bull World Health Organ; 1956; 14(4):613-6. PubMed ID: 13356138
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.